Signal Genetics' MyPRS(R) Highlighted in the Journal Leukemia

Signal Genetics, Inc.(NASDAQ: SGNL) (Signal), a commercial stage, molecular genetics diagnosticcompany focused on providing innovative diagnostic services that helpphysicians make better-informed decisions concerning the care of theirpatients suffering from cancer, today announced that a peer-reviewed paperhighlighting the clinical utility of MyPRS(R) in the everyday management ofpatients with multiple myeloma, was published on-line in the journalLeukemia on November 3, 2015. In the paper, titled "The Clinical Value of Molecular Subtyping MultipleMyeloma Using Gene Expression Profiling", authored by N. Weinhold et al.,researchers examined a dataset of 1,217 multiple myeloma patients treated atthe Myeloma Institute at the University of Arkansas for Medical Sciences(UAMS) to gauge the impact of novel therapies on molecular and risksubgroups. As part of the research, Signal's MyPRS(R) genetic test (alsoknown as the GEP70 test) was used to classify patients into risk categoriesand molecular subtypes. The outcome of this research demonstrates theimportance of classifying the risk category and subtype of a patient'scancer in order to appropriately manage the course of treatment. This isespecially true for "high risk" patients that have a very aggressive form ofmultiple myeloma, and therefore may require an unconventional therapeuticapproach. Samuel D. Riccitelli, President and CEO of Signal, commented, "Having thispeer-reviewed paper accepted by Leukemia is a very important and excitingevent for Signal and our MyPRS(R) genetic test. Leukemia is one of the mostrespected medical journals in its field, and acceptance of this paper isclear validation of the value of MyPRS(R) in the management of patients withmultiple myeloma." Mr. Riccitelli, continued, "This research clearly shows that patients withcertain subtypes of multiple myeloma will respond differently to specifictherapies. Further, the data outlined in this paper demonstrate the need toclassify the risk category along with the subtype in order to fullyunderstand which treatment option is optimal for the patient. Knowing whattreatments will or will not work for a patient is absolutely critical whendealing with this potentially fatal disease, and our assay has proven ableto classify both risk category and subtype of multiple myeloma to aidphysicians as they seek to achieve the best outcome for their patients.While MyPRS(R) is already used in a significant number of cases at leadingacademic centers in the U.S., this paper supports the advantage for ourgenetic test to be used as a standard of care in the management of multiplemyeloma patients." Gareth Morgan, M.D., FRCP, FRCPath, Ph.D., Professor of Medicine andDirector of the Myeloma Institute at UAMS, commented. "Through significanttime and research, the treatment paradigm for multiple myeloma continues toevolve. We actually gain a better appreciation for the severity of thiscancer through a deeper understanding of its complexity. This complexity haspushed researchers to develop multiple therapeutic options to treat thedisease, and with several classes of therapies available - and many more inclinical trials - the ability to classify patients by both risk level andsubtype has emerged as a critical input to determine choice of therapy. Thedata now published in Leukemia suggest that MyPRS(R) may be the right toolto inform treatment decisions and achieve better outcomes for patientsliving with multiple myeloma, one of the most challenging cancers in thefield." Signal Genetics has developed its MyPRS(R) prognostic test to enhance thetreatment of patients suffering from multiple myeloma. This proprietaryassay enables physicians to accurately stratify patients into high andlow-risk categories and molecular disease subtypes, in order to ensure theyare receiving the most appropriate level of care to prevent over treating orunder treating the disease.